XM does not provide services to residents of the United States of America.
B
B

Brembo

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Barratt Redrow, Genuit Group, Munich Re

EUROPE RESEARCH ROUNDUP-Barratt Redrow, Genuit Group, Munich Re Oct 21 (Reuters) - Securities analysts revised their ratings and price targets on several European companies including Barratt Redrow, Genuit Group and Munich Re, on Monday. HIGHLIGHTS * Barratt Redrow Plc BTRW.L : Morgan Stanley raises to overweight from equal-weight * Genuit Group Plc GENG.L : JP Morgan initiates coverage with neutral rating; PT 535p * Intertek ITRK.L : RBC cuts to sector perform from outperform * Munich Re MUVGn.
B
B
B
B
B
C
D
D
E
E
E
F
G
N
O
R
S
A
P

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Adds: CVS, Frasers Group, Tetragon, Oct 11 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Friday: * * CVS Health CVS.N is exiting its core infusion services business and plans to either close or sell 29 related regional pharmacies in the coming months, a company spokesperson confirmed to Reuters on Friday.
A
A
B
S
U

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Updates: Nippon Steel Oct 11 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1330 GMT on Friday: ** Nippon Steel 5401.T said it will sell its entire 50% stake in a joint-venture steel plant it has in Calvert, Alabama, with ArcelorMittal MT.LU , if the top Japanese steelmaker succeeds in a buyout bid for United States Steel X.N .
A
A
B
S
U

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Oct 11 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 0930 GMT on Friday: ** Sanofi SASY.PA has entered into talks to sell a controlling 50% stake in its consumer health business Opella to U.S. private equity firm Clayton Dubilier & Rice, the French pharmaceutical group said.
A
A
B
S
U

Italy's Brembo jumps after acquisition of suspension maker Öhlins Racing

BUZZ-Italy's Brembo jumps after acquisition of suspension maker Öhlins Racing ** Shares in Italian premium brake maker Brembo BRBI.MI rise 4.3% after it agreed to buy Swedish suspension technology manufacturer Öhlins Racing for $405 million ** The deal is the largest acquisition in Brembo's history, it says ** Brokerage Equita says Brembo paid an
B

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.